BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 12621385)

  • 1. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
    Kharasch ED; Bedynek PS; Hoffer C; Walker A; Whittington D
    Anesthesiology; 2012 Feb; 116(2):432-47. PubMed ID: 22273859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.
    Belle DJ; Callaghan JT; Gorski JC; Maya JF; Mousa O; Wrighton SA; Hall SD
    Br J Clin Pharmacol; 2002 Jan; 53(1):67-74. PubMed ID: 11849197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.
    Kharasch ED; Whittington D; Ensign D; Hoffer C; Bedynek PS; Campbell S; Stubbert K; Crafford A; London A; Kim T
    Clin Pharmacol Ther; 2012 Apr; 91(4):673-84. PubMed ID: 22398970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism.
    Lee JS; Kim SH
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31284540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pupillary unrest, opioid intensity, and the impact of environmental stimulation on respiratory depression.
    McKay RE; Kohn MA; Larson MD
    J Clin Monit Comput; 2022 Apr; 36(2):473-482. PubMed ID: 33651243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia.
    Lötsch J; Skarke C; Darimont J; Zimmermann M; Bräutigam L; Geisslinger G; Ultsch A; Oertel BG
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Oct; 386(10):865-73. PubMed ID: 23775505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
    Kharasch ED; Francis A; London A; Frey K; Kim T; Blood J
    Clin Pharmacol Ther; 2011 Jul; 90(1):100-8. PubMed ID: 21562488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry.
    Kim T; London A; Kharasch ED
    J Pharm Biomed Anal; 2011 Jun; 55(3):487-93. PubMed ID: 21382685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
    Kharasch ED; Vangveravong S; Buck N; London A; Kim T; Blood J; Mach RH
    Clin Pharmacol Ther; 2011 Apr; 89(4):562-70. PubMed ID: 21346758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
    Zhou S; Chan E; Li X; Huang M
    Ther Clin Risk Manag; 2005 Mar; 1(1):3-13. PubMed ID: 18360537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Björkman S
    Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
    Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
    Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
    Kharasch ED; Hoffer C; Whittington D
    Br J Clin Pharmacol; 2004 May; 57(5):600-10. PubMed ID: 15089813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
    Kharasch ED; Hoffer C; Walker A; Sheffels P
    Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.